AFAngela J. Forbes

Angela J. Forbes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angela J. Forbes has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis

    by Charles N Bernstein, Gilaad G Kaplan, Zoann Nugent, Vineet Ahuja, Ashwin N Ananthakrishnan, Rupa Banerjee, Johan Burisch, Yan Chen, David Epstein, Angela J Forbes, et al.

    Background: The aim of this study was to determine if Crohn’s disease (CD) and ulcerative colitis (UC) manifest similarly in different parts of the world. Methods: Investigators of cohort studies from around the world were contacted to provide the most recent data from their CD and UC cohorts. Each cohort provided summated and averaged data on pre-specified variables. The Montreal Classification was used for phenotype assessment. Age at diagnosis was stratified into less than 17 years, 17-39 years, and >39 years. Disease location for CD was stratified as ileum only, colon only, ileocolon, upper gastrointestinal and proximal small bowel disease, and perineal penetrating disease. Disease behavior for CD was stratified into inflammatory disease, stricturing disease, and penetrating disease. Location for UC was stratified into proctitis, left-sided colitis, and extensive including subtotal and pancolitis. Reports were classified geographically as Asia, Latin America, South Africa, and “Western” (ie, North America, Europe, and Oceania). These categories were collapsed to “Western” and “non-Western” for analyses. Results: Data from 54 868 patients with IBD were included. For CD, data were available from nine Western cohorts, 12 Asian cohorts, three Latin American cohorts, and one African cohort. For UC, eight Western cohorts were compared with 11 Asian cohorts, three Latin cohorts, and one African cohort. The demographic and phenotypic distribution for CD and UC in comparisons between Western and non-Western countries were no different. Western cohorts had longer disease durations than non-Western cohorts Conclusion: No significant differences were seen in any phenotypic data between the cohorts, suggesting that IBD is similar worldwide.


  • Open Access

    The Incidence of Inflammatory Bowel Disease in Otago, New Zealand 1996–2024: A 28‐Year Analysis

    by Jahman Cochrane, Angela J. Forbes, Kirsten J. Coppell, Michael Schultz

    Introduction: Epidemiological measures of inflammatory bowel disease (IBD) evaluate the current and future burden of IBD on the health system. Long‐run incidence studies can identify changes in disease patterns and potentially give clues about aetiology if environmental risk factors have also changed. Methods: Clinic records and databases were retrospectively searched for adults and children diagnosed with IBD in the Otago region, southern New Zealand to the end of 2024. Medical chart review confirmed cases using standard IBD diagnostic criteria, and the Montreal phenotype, diagnostic delay, medical and surgical treatments were extracted. Previous data from Otago were included to compare incidence over time. Results: Between 2014 and 2024, there were 438 patients diagnosed with IBD in Otago, giving an average annual incidence rate of 19.7 per 100,000 (95% CI 17.9–21.6). The rates of Crohn's disease (CD) and ulcerative colitis (UC) were 8.5 (95% CI 7.4–9.8) and 10.6 (9.3–12.0) per 100,000, respectively. Most (87%) patients were of NZ European ethnicity. Individuals with CD had a lower median age (years) at diagnosis: 25.5, compared to those with UC: 40, ( p < 0.001). The median diagnostic delay was 6 months (IQR 3–9). Comparing the most recent decade (2014–2024) with previous data (1996–2013), the incidence of IBD rose from 14.2 to 19.7 per 100,000, ( p < 0.001). Over that period, the CD increase did not reach statistical significance, whereas the UC increase did. Conclusion: This long‐run incidence study observed the incidence of IBD in Otago continues to increase, representing a growing burden to patients and the health system.

  • Incidence, prevalence and mortality of inflammatory bowel disease in New Zealand 2006–2022 using hospital information in the Integrated Data Infrastructure ( IDI )

    by Angela J. Forbes, Sheree J. Gibb, Nicholas Bowden, Andrew S. Day, Chris M. A. Frampton, Richard B. Gearry

    Introduction: The epidemiology of inflammatory bowel disease (IBD) in New Zealand (NZ) has been explored in regional studies but not at a national level. This study aimed to use administrative data to define the first nationwide IBD population and estimate the incidence, prevalence and mortality of IBD in NZ. Methods: The Integrated Data Infrastructure (IDI) is a statistical database linking population‐level health data. An IBD population was created within the IDI using hospital discharge information by International Classification of Diseases, Tenth Revision code. Incidence and prevalence rates were calculated for 16 years (2006/07–2021/22) by age, sex, ethnicity and urban/rural location. Age‐sex‐standardised mortality was measured annually from 2012 to 2022. Results: Between 1 July 2021 and June 30 2022, 19 566 people in the IDI were identified as having IBD, giving a prevalence of 391.4 (95% confidence interval (CI) 386.0–396.9) per 100 000 people. The prevalence of Crohn's disease (CD), 206.9 (95% CI 203.0–211.0), was similar to that of ulcerative colitis (UC), 213.2 (95% CI 209.2–217.2), both per 100 000 people. In the same year, 1407 new cases of IBD were observed, giving an incidence rate of 28.1 (95% CI 26.7–29.7) per 100 000 person‐years. The 2012–2022 standardised mortality ratio for IBD was 1.69 (95% CI 1.60–1.79). Conclusions: A high incidence and prevalence of IBD were seen in NZ, and increased all‐cause mortality rates were observed. Despite the limitations of using hospital data, this work established the value of IDI data for IBD epidemiological studies and produced national estimates of IBD burden.

  • 20-Year Mortality in a Population-Based Cohort of Patients with Inflammatory Bowel Disease from New Zealand

    by Angela J. Forbes, Chris M. A. Frampton, Andrew S. Day, Richard B. Gearry

    Inflammatory bowel disease (IBD) can lead to mortality directly through severe disease or indirectly via increased risk of malignancy or infection. There are few studies of IBD mortality from the Southern Hemisphere, while new treatments have become available. We aimed to measure 20-year mortality from a population-based IBD cohort in Canterbury, New Zealand. A prevalent cohort of 1420 patients with IBD and 600 controls, both recruited in 2005, were followed to 2024. Medical record review identified the underlying cause of death. Standardized mortality ratios compared the deaths in the IBD cohort with those in the general population. Risks were assessed using hazard ratios from Cox regression analysis. During the 23,558 person-years of follow-up, 366 (25.9%) patients with IBD died, at an average age of 75.3 years (SD 13.7). More patients with ulcerative colitis (UC) (n = 195; 29.4%) than Crohn's disease (CD) (n = 162; 22.8%) died. Fewer (18.4%) of the matched control participants died. The SMR for IBD was 1.23 (95% CI 1.11-1.36), with the SMR for CD being 1.42 (1.21-1.65) and UC 1.18 (1.02-1.35). Older age and primary sclerosing cholangitis (PSC) were associated with an increased risk of mortality. Smoking was associated with CD mortality and cancer with UC mortality. Common causes of death included cancer, heart disease, and pneumonia. Patients with IBD from this population-based cohort were at increased risk of all-cause mortality over the 20-year follow-up. CD had a higher mortality rate than UC and patients with concomitant PSC were at particular risk.


  • Open Access

    Compounding Prevalence of Inflammatory Bowel Disease in a 2024 Population‐Based Study From Canterbury, New Zealand

    by Angela J. Forbes, Andrew S. Day, Chris M. A. Frampton, Richard B. Gearry

    Background and Aim: The epidemiological patterns of inflammatory bowel disease (IBD) can give insights into disease etiology and health system burden. This study aimed to measure the population‐based prevalence in Canterbury and consider the region's position within the 4‐stage epidemiological model of IBD.Methods: Gastroenterology clinics in Canterbury were searched for patients with a confirmed diagnosis of IBD. Demographic and disease details (including Montreal phenotype) were extracted from individual medical records. The prevalence of IBD, Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU) was established for the total population and for age, sex, and ethnic sub‐groups.Results: Altogether 4042 individuals (1 in 150 people) in Canterbury with IBD were identified. The point prevalence of IBD on 1st January 2024 was 671 (95% CI 651–692) per 100 000 persons. The prevalence of CD 386 (95% CI 370–402) was higher than UC 264 (95% CI 251–277) each per 100 000. Almost three times as many individuals had IBD in 2024, compared to a 2005 study. The majority of the cohort were New Zealand European (92.9%) followed by Māori (4.2%), Asian (2.6%) and Pacific peoples (0.3%). Older adults (65+ years) comprised 21% of the population with a prevalence of 845 (95% CI 789–904) per 100 000 persons.Conclusion: Canterbury has the highest reported prevalence of IBD in Oceania to date, and there is a growing proportion of older age patients. The rapid rise in cases supports the hypothesis that Canterbury is in the compounding prevalence stage of the epidemiological model of IBD.


  • Top Cited Papers
    Open Access

    Global evolution of inflammatory bowel disease across epidemiologic stages

    by Lindsay Hracs, Joseph W. Windsor, Julia Gorospe, Michael Cummings, Stephanie Coward, Michael J. Buie, Joshua Quan, Quinn Goddard, Léa Caplan, Ante Markovinović, et al.

    During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.


  • Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand, 2018–2023

    by Angela J. Forbes, Andrew S. Day, Chris M. A. Frampton, Richard B. Gearry

    Background New diagnoses of inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), can highlight health system burden and potentially give clues to disease aetiology. This population-based study aimed to measure the annual incidence of IBD over six years (2018–2023) in the Canterbury region of New Zealand. Methods The medical records from public and private gastroenterology clinics were examined for new patients with a confirmed diagnosis of IBD from 1 January 2018 to 31 December 2023. Demographic and disease information (including the Montreal phenotype) was gathered in a secure database. Information was collected prospectively from 2021 to 2023 and retrospectively from 2018 to 2020. Results The incidence of IBD in 2023 was 30.1 per 100,000 person-years (95% CI 25.9–34.7), CD: 14.8 (95% CI 11.9–18.1), and UC: 14.5 (95% CI 11.7–17.7). The average age was 35.0 years (SD 17.2) and New Zealand European was the predominant ethnicity (83.4%), with smaller proportions of Māori (7.7%) and Pacific Islanders (1.7%). Between 2018 and 2023, the annual incidence of IBD was 32.4 per 100,000 person-years. The proportion of CD diagnosed each year decreased, and in 2023, the proportion of CD was equivalent (49%) to the proportion with UC. Conclusions The incidence of IBD in Canterbury remains high, and the rates appeared stable over the six years 2018–2023, consistent with the stabilizing incidence stage of the 4-stage epidemiological model of IBD. Māori and Pacific Island ethnicities contributed a small number of cases of IBD, but the rates of IBD in these groups were higher than in previous studies.


  • Open Access

    Ten‐year outcomes of a prospective population‐based incidence cohort of inflammatory bowel disease patients from Canterbury, New Zealand

    by Angela J Forbes, Chris M A Frampton, Andrew S Day, Millie DeVries, Nina McVicar, Heidi Su, Richard B Gearry

    Background and Aim: Inflammatory bowel disease (IBD) is a progressive condition where ongoing inflammation in the gastrointestinal tract can lead to complications such as strictures, and fistulae. The long‐term outcomes of newly diagnosed patients under current medical therapy can be used to plan health service provision and guide patients.Methods: Prospective population‐based data on all incident patients diagnosed with IBD in Canterbury was gathered in 2014 (n = 205). The medical records of these patients were followed for medication use, disease progression, hospitalization, surgery and mortality, in the 10 years since their diagnosis. Survival analysis and cox regression determined characteristics associated with earlier time to these outcomes.Results: Medical records of 184 IBD patients were able to be retrieved. Immunomodulators were used by 62% and biologics by 35%; hospitalization occurred for 42% and surgery for 15%. Montreal phenotype progression occurred for 21 and 7% of the cohort died. Younger age at diagnosis hazard ratio (HR) 2.1 (95% confidence interval [CI] 1.1–4.0) and Crohn's disease HR 1.7 (95% CI 1.1–2.6) was associated with immunomodulator use. Younger age was also associated with biologic use HR 2.9 (95% CI 1.2–6.9). Male gender was associated with surgery HR 2.8 (95% CI 1.2–6.4). Perianal disease at diagnosis (14.7%) was associated with immunomodulator use HR 2.58 (95% CI 1.44–4.59) and Montreal phenotype progression HR 2.93 (95% CI 1.10–7.77).Conclusion: In the 10 years since diagnosis disease progression and treatment escalation occurred for most of this population‐based cohort. Earlier intervention for patients with higher‐risk characteristics may improve long‐term outcomes reducing the burden on health systems.